Committee for Orphan Medicinal Products
E24718
The Committee for Orphan Medicinal Products is a specialized expert body that evaluates and advises on the designation and development of medicines for rare diseases within the European Union.
All labels observed (3)
How this entity was disambiguated
This entity first appeared as the object of triple T184503 — resolving that mention is where its identity was fixed. The disambiguator weighed these candidate entities and picked the highlighted one (or “None”, minting a new entity). This is how homonymy is resolved: the same surface form can point to different entities.
NED1
Entity disambiguation (via context triple)
gpt-5-mini-2025-08-07
Target entity: Committee for Orphan Medicinal Products Context triple: [European Medicines Agency, hasCommittee, Committee for Orphan Medicinal Products]
-
A.
Committee for Proprietary Medicinal Products
The Committee for Proprietary Medicinal Products was a former scientific committee of the European Union responsible for evaluating and issuing opinions on the quality, safety, and efficacy of human medicinal products before it was replaced by the European Medicines Agency’s current committee structure.
-
B.
European Medicines Agency
The European Medicines Agency is the European Union’s regulatory authority responsible for the scientific evaluation, supervision, and safety monitoring of medicines for human and veterinary use.
-
C.
Committee for Advanced Therapies
The Committee for Advanced Therapies is a scientific body within the European Medicines Agency responsible for evaluating and providing expert opinions on advanced therapy medicinal products such as gene, cell, and tissue-engineered therapies.
-
D.
International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use
The International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use (ICH) is a global body that develops and promotes unified scientific and technical standards to ensure the safety, quality, and efficacy of medicines worldwide.
-
E.
Committee for Medicinal Products for Veterinary Use
The Committee for Medicinal Products for Veterinary Use is the European Medicines Agency’s scientific committee responsible for evaluating and providing opinions on veterinary medicines in the European Union.
- F. None of above. chosen
- G. Unsure - the case is ambiguous/there is not enough information to decide.
NED2
Entity disambiguation (via description)
gpt-5-mini-2025-08-07
Target entity: Committee for Orphan Medicinal Products Target entity description: The Committee for Orphan Medicinal Products is a specialized expert body that evaluates and advises on the designation and development of medicines for rare diseases within the European Union.
-
A.
Committee for Proprietary Medicinal Products
The Committee for Proprietary Medicinal Products was a former scientific committee of the European Union responsible for evaluating and issuing opinions on the quality, safety, and efficacy of human medicinal products before it was replaced by the European Medicines Agency’s current committee structure.
-
B.
European Medicines Agency
The European Medicines Agency is the European Union’s regulatory authority responsible for the scientific evaluation, supervision, and safety monitoring of medicines for human and veterinary use.
-
C.
Committee for Advanced Therapies
The Committee for Advanced Therapies is a scientific body within the European Medicines Agency responsible for evaluating and providing expert opinions on advanced therapy medicinal products such as gene, cell, and tissue-engineered therapies.
-
D.
International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use
The International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use (ICH) is a global body that develops and promotes unified scientific and technical standards to ensure the safety, quality, and efficacy of medicines worldwide.
-
E.
Committee for Medicinal Products for Veterinary Use
The Committee for Medicinal Products for Veterinary Use is the European Medicines Agency’s scientific committee responsible for evaluating and providing opinions on veterinary medicines in the European Union.
- F. None of above. chosen
Statements (47)
| Predicate | Object |
|---|---|
| instanceOf |
European Union body
ⓘ
expert body ⓘ regulatory advisory committee ⓘ scientific committee ⓘ |
| abbreviation | COMP ⓘ |
| appliesTo | human medicinal products ⓘ |
| collaboratesWith |
European Commission
ⓘ
national competent authorities of EU Member States ⓘ patient organizations ⓘ pharmaceutical industry ⓘ |
| composition |
experts in rare diseases and orphan drugs
ⓘ
members nominated by EU Member States ⓘ members nominated by the European Commission ⓘ patient representatives ⓘ |
| country | European Union ⓘ |
| field |
drug development
ⓘ
orphan medicinal products ⓘ pharmaceutical regulation ⓘ rare diseases ⓘ |
| focus | conditions affecting not more than 5 in 10,000 people in the EU ⓘ |
| goal |
facilitate development and availability of orphan medicines in the EU
ⓘ
improve treatment options for patients with rare diseases ⓘ |
| grants | opinions that can lead to market exclusivity incentives ⓘ |
| inception | 2000 ⓘ |
| jurisdiction | European Union ⓘ |
| language | English ⓘ |
| legalBasis |
Regulation (EC) No 141/2000
ⓘ
Regulation (EC) No 726/2004 ⓘ |
| locatedIn |
Amsterdam
ⓘ
Netherlands ⓘ |
| meetsAt | European Medicines Agency headquarters ⓘ |
| parentOrganization | European Medicines Agency ⓘ |
| partOf | European Medicines Agency ⓘ |
| provides | scientific advice on orphan drug development strategies ⓘ |
| regulates | orphan medicinal product designation in the EU ⓘ |
| role |
advise on development of medicines for rare diseases
ⓘ
advise the European Commission on orphan medicinal products ⓘ contribute to guidelines on orphan drug development ⓘ evaluate applications for orphan designation of medicines ⓘ provide opinions on orphan medicinal product designation ⓘ support implementation of EU orphan drug legislation ⓘ |
| subjectOf | EU orphan drug policy ⓘ |
| typeOfJurisdiction | supranational ⓘ |
| website | https://www.ema.europa.eu/en/committees/committee-orphan-medicinal-products-comp ⓘ |
| worksOn |
orphan designation procedures
ⓘ
protocol assistance for orphan medicines ⓘ review of maintenance or withdrawal of orphan designation ⓘ |
How these facts were elicited
The pipeline generated the facts above by prompting gpt-5.1 with this entity's name + description and the instruction below.
Instruction
You are a knowledge base construction expert. Given a subject entity and a description of it, return factual statements that you know for the subject as a JSON list of dictionaries(triples), where keys must be "subject", "predicate" and "object". The number of facts may be very high, between 25 to 50 or more, for very popular subjects. For less popular subjects, the number of facts can be very low, like 5 or 10. # Requirements - If you don't know the subject at all, return an empty list. - If the subject is not a named entity, return an empty list. - Include at least one triple where predicate is "instanceOf". - Do not get too wordy. - Separate several objects into multiple triples with one object.
Input
Subject: Committee for Orphan Medicinal Products Description of subject: The Committee for Orphan Medicinal Products is a specialized expert body that evaluates and advises on the designation and development of medicines for rare diseases within the European Union.
Referenced by (11)
Full triples — surface form annotated when it differs from this entity's canonical label.
subject linked to:
EMA
Regulation (EC) No 726/2004
→
establishes
→
Committee for Orphan Medicinal Products within the European Medicines Agency
ⓘ
linked to: Committee for Orphan Medicinal Products
subject linked to:
CAT
Committee for Medicinal Products for Human Use
→
worksWith
→
Committee for Orphan Medicinal Products
ⓘ
Regulation (EC) No 141/2000 on orphan medicinal products
→
establishes
→
Committee for Orphan Medicinal Products
ⓘ
Regulation (EC) No 141/2000 on orphan medicinal products
→
implementedBy
→
Committee for Orphan Medicinal Products
ⓘ
linked to: Committee for Orphan Medicinal Products